Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors
Status:
Withdrawn
Trial end date:
2019-11-19
Target enrollment:
Participant gender:
Summary
This study is a single arm, pilot study of Sorafenib in patient with BRAF mutation Refractory
solid tumor and specific sensitivity to Sorafenib by Avatar scan that has progressed
following standard therapy or that has not responded to standard therapy or for which there
is no standard therapy.
To investigate the efficacy and safety of Sorafenib in patient with Refractory solid tumor.